Drugs / Desmopressin
Desmopressin
also known as
DDAVP · Desmopressin Acetate · SER120 · Minirin · 1 deamino 8 D argininevasopressin · 1-desamino-8-d-arginine vasopressin · Stimate Nasal Spray
Regulatory milestones approvals, filings & regulatory actions · 3 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansion | US (FDA) | DDAVP | — | 1998-03-25 | fda.gov ↗ |
| Label expansion | US (FDA) | DDAVP (NEEDS NO REFRIGERATION) | — | 1989-11-28 | fda.gov ↗ |
| Approved | US (FDA) | DDAVP (NEEDS NO REFRIGERATION) | — | 1978-02-21 | fda.gov ↗ |
Trials 69 · started per year
today
US approved 1978
2
1
3
1
2
2
4
5
7
7
7
1
1
2
5
1
3
3
1
7
1
3
19771978197919801981198219831984198519861987198819891990199119921993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023202420252026202720282029
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT04113005 | Oct 2019 → Apr 2020 | castration-resistant prostate carcinoma | Sunnybrook Health Sciences Centre | Unknown | No outcome recorded |
| Phase 14 trials · 1 met primary | ||||||
| Phase 1 | NCT04103034 | Oct 2019 → Sep 2020 | intracranial arteriosclerosis, large artery stroke | Band Therapeutics | Completed | No outcome recorded |
| Phase 1 | NCT01841515 | Aug 2012 → Apr 2013 | cardiac rhythm disease, hemorrhagic disease | University of Ulsan | Completed | No outcome recorded |
| Phase 1 | NCT00835211 | Jul → Aug 2003 | — | Teva Pharmaceuticals USA | Completed | Met primary |
| Phase 1 | NCT00223717 | Jan 2001 → Jan 2017 | hypertensive disorder | Vanderbilt University | Completed | No outcome recorded |
| Phase 212 trials · 2 met primary · 1 missed | ||||||
| Phase 2 | NCT06635629 | Dec 2024 → Oct 2028 expected | Cushing syndrome | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Recruiting | No outcome recorded |
| Phase 2 | NCT04586790 | Oct 2020 → Jan 2021 | — | Ahmed talaat ahmed aly | Unknown | No outcome recorded |
| Phase 2 | NCT03696121 | Apr 2019 → Jun 2022 | stroke disorder | University of Nottingham | Completed | No outcome recorded |
| Phase 2 | NCT03201419 | Jul 2017 → Oct 2019 | — | Ferring Pharmaceuticals | Completed | Met primary |
| Phase 2 | NCT01982760 | Dec 2013 → Jun 2015 | — | University Hospitals Cleveland Medical Center | Terminated | No outcome recorded |
| Phase 2 | NCT01779466 | Apr 2013 → Jun 2014 | nocturnal enuresis | Ferring Pharmaceuticals | Terminated | No outcome recorded |
| Phase 2 | NCT01623206 | Apr 2013 → Jul 2017 | colorectal cancer | Laboratorio Elea Phoenix S.A. | Completed | No outcome recorded |
| Phase 2 | NCT01729819 | Jan 2013 → Nov 2014 | overactive bladder | Ferring Pharmaceuticals | Completed | Missed primary |
| Phase 2 | NCT01606072 | Nov 2011 → Feb 2015 | breast cancer | Laboratorio Elea Phoenix S.A. | Completed | No outcome recorded |
| Phase 2 | NCT00961532 | Dec 2010 → Dec 2013 | intracerebral hemorrhage | Northwestern University | Completed | No outcome recorded |
| Phase 2 | NCT01184859 | Jul 2010 → Apr 2011 | nocturnal enuresis | Ferring Pharmaceuticals | Completed | Met primary |
| Phase 2 | NCT00632242 | Jan → Dec 2008 | thrombotic thrombocytopenic purpura, von Willebrand disease type 2B | Archemix Corp. | Completed | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT01357356 | May 2011 → Oct 2012 | nocturnal enuresis | Serenity Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 2/3 | NCT00592566 | Jul 2003 → Oct 2006 | leptospirosis | Mahidol University | Terminated | No outcome recorded |
| Phase 321 trials · 4 met primary · 1 missed | ||||||
| Phase 3 | NCT06337838 | Jun 2025 → Feb 2027 expected | acute kidney injury, chronic kidney disease, hemorrhagic disease | Hamilton Health Sciences Corporation | Recruiting | No outcome recorded |
| Phase 3 | NCT06020495 | Dec 2024 → Sep 2026 overdue | — | Assistance Publique - Hôpitaux de Paris | Recruiting | No outcome recorded |
| Phase 3 | NCT05467033 | Sep 2022 → Aug 2026 overdue | — | Medical University of Bialystok | Recruiting | No outcome recorded |
| Phase 3 | NCT03051009 | Jan 2017 → Sep 2018 | — | Ferring Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT02905682 | Sep 2016 → Sep 2017 | — | Ferring Pharmaceuticals | Completed | Missed primary |
| Phase 3 | NCT02904759 | Sep 2016 → Sep 2017 | nocturnal enuresis | Ferring Pharmaceuticals | Completed | Met primary |
| Phase 3 | NCT01900704 | Aug 2013 → Apr 2015 | nocturnal enuresis | Serenity Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT02538302 | Jul 2013 → Jul 2015 | nocturnal enuresis | Hormozgan University of Medical Sciences | Completed | No outcome recorded |
| Phase 3 | NCT01742689 | Mar 2012 → Mar 2013 | urinary tract obstruction | Tehran University of Medical Sciences | Unknown | No outcome recorded |
| Phase 3 | NCT01552343 | Mar → May 2012 | nocturnal enuresis | Ferring Pharmaceuticals | Completed | Mixed |
| Phase 3 | NCT01530451 | Mar 2012 → Feb 2015 | obstructive sleep apnea syndrome | Chinese University of Hong Kong | Terminated | No outcome recorded Stop: Business |
| Phase 3 | NCT01262456 | Feb 2011 → Jan 2012 | — | Ferring Pharmaceuticals | Completed | Met primary |
| Phase 3 | NCT01280188 | Jan → Aug 2011 | central diabetes insipidus | Ferring Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT01223937 | Nov 2010 → Nov 2011 | nocturnal enuresis | Ferring Pharmaceuticals | Completed | Met primary |
| Phase 3 | NCT01259128 | Apr → Nov 2010 | nocturnal enuresis | Serenity Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT01078753 | Jan → Sep 2010 | nocturnal enuresis | Ferring Pharmaceuticals | Completed | Met primary |
| Phase 3 | NCT00981682 | Aug 2009 → Jun 2011 | nocturnal enuresis | Serenity Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00937859 | Jun 2009 → Jul 2010 | — | Serenity Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00937378 | Jun 2009 → Aug 2010 | — | Serenity Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT00615836 | Dec 2007 → May 2010 | nocturnal enuresis | Ferring Pharmaceuticals | Completed | No outcome recorded |
| Phase 3 | NCT00477490 | May 2007 → Feb 2008 | — | Ferring Pharmaceuticals | Completed | Mixed |
| Phase 416 trials · 2 met primary | ||||||
| Phase 4 | NCT07712328 | Jun 2026 → May 2028 expected | craniopharyngioma, pituitary gland adenoma | Zhaoyun Zhang | Enrolling by invitation | No outcome recorded |
| Phase 4 | NCT06622187 | Aug 2024 → Jun 2026 overdue | hemorrhagic disease | Hospital de Clinicas de Porto Alegre | Enrolling by invitation | No outcome recorded |
| Phase 4 | NCT06255366 | Mar → Dec 2024 | osteoarthritis, spine, spondylolisthesis | Chengdu University of Traditional Chinese Medicine | Unknown | No outcome recorded |
| Phase 4 | NCT04420585 | Jul 2020 → Jun 2023 | nocturnal enuresis, sickle cell disease | Montefiore Medical Center | Terminated | No outcome recorded Stop: Enrollment |
| Phase 4 | NCT04545931 | Mar → Nov 2020 | enuresis, nocturnal, 1 | Cairo University | Unknown | No outcome recorded |
| Phase 4 | NCT03389412 | Oct 2017 → Jan 2023 | enuresis, nocturnal, 1 | University of Aarhus | Completed | No outcome recorded |
| Phase 4 | NCT02584231 | Sep 2015 → Mar 2018 | nocturnal enuresis | University Ghent | Completed | No outcome recorded |
| Phase 4 | NCT02125188 | Jan → Aug 2014 | — | Tao Zhang | Completed | No outcome recorded |
| Phase 4 | NCT01582542 | Apr 2012 → Dec 2013 | nocturnal enuresis | Rabin Medical Center | Unknown | No outcome recorded |
| Phase 4 | NCT01439997 | Mar 2012 → Feb 2013 | — | University Hospital, Ghent | Completed | No outcome recorded |
| Phase 4 | NCT01435083 | Nov 2011 → Jun 2013 | — | University Hospital, Ghent | Completed | No outcome recorded |
| Phase 4 | NCT01645475 | Apr 2011 → Aug 2012 | nocturnal enuresis | University Hospital, Ghent | Completed | Met primary |
| Phase 4 | NCT01994330 | Jun → Dec 2009 | acquired von willebrand syndrome, aortic valve stenosis | Pontificia Universidad Catolica de Chile | Completed | No outcome recorded |
| Phase 4 | NCT00748072 | Aug 2008 → Aug 2009 | kidney failure | University of Bari | Completed | Met primary |
| Phase 4 | NCT00902655 | Apr 2004 → Dec 2005 | — | Samsung Medical Center | Completed | No outcome recorded |
| Phase 4 | NCT00245479 | Apr 2002 → Sep 2005 | nocturnal enuresis | Ferring Pharmaceuticals | Completed | No outcome recorded |
| Phase not applicable13 trials | ||||||
| — | NCT07855315 | Oct 2026 → Oct 2027 expected | chronic rhinosinusitis, nasal cavity polyp | Services Institute of Medical Sciences, Pakistan | Not yet recruiting | No outcome recorded |
| — | NCT04569591 | Mar 2026 → Feb 2028 expected | Cushing disease due to pituitary adenoma | National Institute of Neurological Disorders and Stroke (NINDS) | Recruiting | No outcome recorded |
| — | NCT07292753 | Dec 2024 → Oct 2025 | nocturnal enuresis, vitamin D deficiency | Ain Shams University | Completed | No outcome recorded |
| — | NCT06771128 | Nov 2024 → Dec 2025 | nocturnal enuresis | Menoufia University | Completed | No outcome recorded |
| — | NCT06285006 | Feb → May 2024 | nocturnal enuresis | Al-Azhar University | Unknown | No outcome recorded |
| — | NCT03733873 | Sep 2018 → Jan 2020 | nocturnal enuresis | Children's Hospital of Fudan University | Completed | No outcome recorded |
| — | NCT07840313 | Aug → Nov 2017 | — | Sindh Institute of Urology and Transplantation | Completed | No outcome recorded |
| — | NCT03054662 | Jan 2017 → Dec 2018 | hemophilia | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | Completed | No outcome recorded |
| — | NCT02084342 | Dec 2013 → Apr 2014 | idiopathic scoliosis | Liu Weifeng | Unknown | No outcome recorded |
| — | NCT02068560 | May 2012 → Dec 2014 | nocturnal enuresis | University of Aarhus | Completed | No outcome recorded |
| — | NCT02084797 | Jun → Oct 2011 | — | Oakland University | Completed | No outcome recorded |
| — | NCT00816127 | Oct 2003 → May 2007 | blood coagulation disease, cirrhosis of liver | Icahn School of Medicine at Mount Sinai | Completed | No outcome recorded |
| — | NCT00111215 | Jan 2001 → Sep 2006 | blood platelet disease, menstrual disorder, von Willebrand disease (hereditary or acquired) | Centers for Disease Control and Prevention | Completed | No outcome recorded |
| Comparator or background therapy25 trials | ||||||
| Phase 1 | NCT02506023 Comparator | Jul 2015 → Jun 2018 | hemophilia A | Emory University | Completed | No outcome recorded |
| Phase 2 | NCT05430048 Comparator | Jul → Oct 2022 | hemorrhagic disease | Zagazig University | Completed | No outcome recorded |
| Phase 2 | NCT01684800 Comparator | Sep 2012 → Jun 2013 | nocturnal enuresis | Ferring Pharmaceuticals | Completed | No outcome recorded |
| Phase 2 | NCT01694498 Comparator | Sep 2012 → Jun 2013 | nocturnal enuresis | Ferring Pharmaceuticals | Completed | No outcome recorded |
| Phase 2/3 | NCT02262936 Comparator | Jul 2015 → Feb 2016 | nocturnal enuresis | Mount Sinai Hospital, Canada | Terminated | No outcome recorded Stop: Enrollment |
| Phase 3 | NCT07012837 Comparator | Jul 2025 → Jul 2027 expected | — | Imam Abdulrahman Bin Faisal University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07199894 Comparator | Dec 2024 → Dec 2025 overdue | nocturnal enuresis | Mansoura University | Recruiting | No outcome recorded |
| Phase 3 | NCT00230594 Comparator | Jul 2004 → Jan 2006 | enuresis, nocturnal, 1 | Ferring Pharmaceuticals | Completed | No outcome recorded |
| Phase 4 | NCT05945420 Comparator | Jul 2023 → Jan 2024 | nocturnal enuresis | Mansoura University | Unknown | No outcome recorded |
| Phase 4 | NCT03676361 Background | Aug 2018 → Apr 2019 | kidney disorder | University of Kansas Medical Center | Withdrawn | No outcome recorded |
| Phase 4 | NCT03343418 Comparator | Feb 2015 → Nov 2017 | blood coagulation disease | Instituto do Coracao | Unknown | No outcome recorded |
| Phase 4 | NCT03510975 Comparator | Jan 2015 → Dec 2017 | nocturnal enuresis | Ankara Training and Research Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01036841 Comparator | Dec 2009 → Apr 2010 | enuresis | University Hospital, Ghent | Completed | No outcome recorded |
| Phase 4 | NCT00902057 Comparator | Jun 2009 → Dec 2010 | — | The University of Hong Kong | Unknown | No outcome recorded |
| Phase 4 | NCT00885924 Comparator | Mar 2009 → Feb 2012 | hemorrhagic disease | St. Olavs Hospital | Terminated | No outcome recorded |
| Phase 4 | NCT00337766 Comparator | Jun 2006 → Sep 2009 | hemorrhagic disease | Vita-Salute San Raffaele University | Completed | No outcome recorded |
| Phase 4 | NCT00209261 Comparator | Dec 2004 → Aug 2005 | enuresis, nocturnal, 1 | Ferring Pharmaceuticals | Completed | No outcome recorded |
| — | NCT06772584 Comparator | Jan → Jul 2024 | nocturnal enuresis | Menoufia University | Completed | No outcome recorded |
| — | NCT06185361 Comparator | Dec 2022 → Mar 2024 | enuresis, nocturnal, 1 | Fayoum University Hospital | Unknown | No outcome recorded |
| — | NCT05617664 Comparator | Nov 2022 → Sep 2023 | nocturnal enuresis | Benha University | Unknown | No outcome recorded |
| — | NCT05507476 Comparator | Sep 2022 → Jun 2023 | — | Zagazig University | Completed | No outcome recorded |
| — | NCT05399173 Comparator | Jun 2022 → Sep 2023 | urethritis | Cairo University | Unknown | No outcome recorded |
| — | NCT02937896 Comparator | Jan 2015 → Feb 2016 | — | Shahid Beheshti University of Medical Sciences | Completed | No outcome recorded |
| — | NCT01382134 Comparator | Jul 2011 → Jul 2012 | platelet disorder, undefined | The University of Hong Kong | Completed | No outcome recorded |
| — | NCT01534117 Comparator | Oct 2009 → Nov 2011 | traumatic brain injury | Chang, Steve S., M.D. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2022-06-21 | Ferring Pharmaceuticals | Regulatory Ferring Statement on Minirin® / Octostim® / DDAVP® / Stimate® (desmopressin) Nasal Spray ferring.com ↗
To resolve this issue, new machinery has been commissioned and a variation application submitted to the European regulatory authorities on Nov 28th, 2024. |
| 2006-01-29 | Teva Branded Pharmaceutical Products R&D, Inc. | Regulatory Teva Announces Approval of Desmopressin Acetate Tablets tevapharm.com ↗
Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) announced today that the U.S. Food and Drug Administration has granted final approval for the Company's ANDA for Desmopressin Acetate Tablets, 0.1 mg and 0.2 mg. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2022-06-21 | Ferring Pharmaceuticals | Ferring Statement on Minirin® / Octostim® / DDAVP® / Stimate® (desmopressin) Nasal Spray ferring.com ↗ |
| 2006-01-29 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Announces Approval of Desmopressin Acetate Tablets tevapharm.com ↗ |
Evidence & citations 11 cited values
Every value below carries the sentence it was read from. 96 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | desmopressin | “The purpose of this study is to investigate how effective and cost saving 1-deamino-8-D-arginine vasopressin (desmopressin, DDAVP) is as opposed to the transfusion of blood...” NCT00816127 ↗78“In another period, subjects will receive a single infusion of desmopressin at a dose of 0.4 mcg/kg given over 30 minutes in combination with a dummy 30-minute stepwise infusion...” NCT00632242 ↗ “the V2 receptor antagonist tolvaptan (Samsca™, 30mg tablet), or the V2 receptor agonist desmopressin (DDAVP™, 0.2mg tablet) was ingested” NCT02084797 ↗ “Desmopressin 0.3 ug/kg of the patient's body weight will be infused over five hours at a rate of 10 ml/hr.” NCT07012837 ↗ “Desmopressin is an antidiuretic available as orally disintegrating lyophilisate (melt) or solid tablet.” PMID 23677249 ↗ May 2013 “eligible to receive the study medication desmopressin once daily as an oral tablet formulation.” PMID 25504157 ↗ Dec 2014 “SER120 (desmopressin)” NCT00981682 ↗ |
| Known as | 1 deamino 8 D argininevasopressin | “The purpose of this study is to investigate how effective and cost saving 1-deamino-8-D-arginine vasopressin (desmopressin, DDAVP) is as opposed to the transfusion of blood...” NCT00816127 ↗1“Desmopressin (1 deamino 8 D argininevasopressin) is a synthetic analog of the antidiuretic hormone L arginine vasopressin.” NCT05430048 ↗ |
| Known as | 1-desamino-8-d-arginine vasopressin | “A phase II dose-escalation trial of perioperative desmopressin (1-desamino-8-d-arginine vasopressin) in breast cancer patients.” PMID 26306290 ↗ Aug 2015 |
| Known as | DDAVP | “The purpose of this study is to investigate how effective and cost saving 1-deamino-8-D-arginine vasopressin (desmopressin, DDAVP) is as opposed to the transfusion of blood...” NCT00816127 ↗19“Desmopressin (DDAVP), already used for patients with von Willebrand syndrome, could reduce bleeding and transfusion requirements in these patients when administered ev (0.3...” NCT00337766 ↗ “Intravenous administration of ovine DDAVP (Desmopressin acetate 10 mcg) results in selective increase in ACTH activity of pituitary adenomas within two minutes and peaks...” NCT04569591 ↗ “We tested the hypothesis that desmopressin (DDAVP), which improves hemostasis through the release of von Willebrand factor, improves platelet activity after intracerebral hemorrhage.” PMID 25005444 ↗ Jul 2014 “Women with menorrhagia who have vWd or who are hemophilia A carriers have also been successfully treated with desmopressin acetate (DDAVP, Stimate® Nasal Spray).” NCT00111215 ↗ “Desmopressin (dDAVP) is a well-known peptide analog of the antidiuretic hormone vasopressin, used to prevent excessive bleeding during surgical procedures.” PMID 26306290 ↗ Aug 2015 “Desmopressin or DDAVP will be administered intravenously (IV) via a nontraumatic peripheral IV line at a dose of 0.3 mcg/kg over 30 minutes.” NCT02506023 ↗ “the V2 receptor antagonist tolvaptan (Samsca™, 30mg tablet), or the V2 receptor agonist desmopressin (DDAVP™, 0.2mg tablet) was ingested” NCT02084797 ↗ “Desmopressin (DDAVP) is a drug which has proven efficacy in improving platelet function in uraemic and cirrhosis patients” NCT01382134 ↗ “Implement the use of DDAVP and antifibrinolytics in patients with haemophilia and symptomatic carriers” NCT03054662 ↗ “Desmopressin (DDAVP) in Patients With Colorectal Cancer and Rectal Bleeding” NCT01623206 ↗ |
| Known as | Desmopressin Acetate | “Oral lyophilisate of desmopressin acetate placed under the participant's tongue, without water, once daily approximately 1 hour before bedtime in the assigned dosage: 10, 25,...” NCT00477490 ↗9“Prophylactic intranasal desmopressin acetate administered before native kidney biopsy in adults with severe renal impairment” NCT07840313 ↗ “Desmopressin acetate (dDAVP) solution for injection” NCT07712328 ↗ “Drug: Desmopressin Acetate 0.2 mg Tablets” NCT06772584 ↗ “DDAVP injection (desmopressin acetate)” NCT00961532 ↗ “Desmopressin Acetate 0.2 mg Tablets” NCT00835211 ↗ “Desmopressin Acetate 0.2 mg Tablets” NCT06771128 ↗ |
| Known as | Minirin | “desmopressin melt form 120 μg (Minirin, Ferring International center, Switzerland) once daily before going to bed” NCT03510975 ↗ |
| Known as | SER120 | “SER120 (desmopressin)” NCT00981682 ↗ |
| Known as | Stimate Nasal Spray | “Women with menorrhagia who have vWd or who are hemophilia A carriers have also been successfully treated with desmopressin acetate (DDAVP, Stimate® Nasal Spray).” NCT00111215 ↗ |
| Action | Activate | “Desmopressin, a synthetic analogue of vasopressin, is a selective agonist of the receptor V2 of vasopressin” NCT01623206 ↗ |
| Modality | Peptide | “Desmopressin (dDAVP) is a well-known peptide analog of the antidiuretic hormone vasopressin” PMID 26306290 ↗ Aug 2015 |
| Route | Oral | “Desmopressin is an antidiuretic available as orally disintegrating lyophilisate (melt) or solid tablet.” PMID 23677249 ↗ May 2013 |